Company intelligence / Profile preview
Schrödinger
New York City, New York, United Statesschrodinger.com ↗
- Ownership
- Public · SDGR
- Employees
- ~800
- Development stage
- Other
01
Overview
Schrödinger has advanced three proprietary small molecule programs into Phase 1 clinical trials targeting hematological malignancies and solid tumors. SGR‑2921 received FDA Fast Track Designation for relapsed/refractory acute myeloid leukemia. The company also maintains a robust portfolio of collaborative drug discovery projects with major pharmaceutical partners.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $2.2B
- Total revenue
- $255.9M
- Enterprise value
- $1.9B
Beyond the preview
Go deeper on Schrödinger.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Schrödinger.